Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $15.14.

Several brokerages have issued reports on CATX. UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $20.00 target price on the stock. Truist Financial initiated coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price target for the company. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday, January 13th. Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, November 22nd. Finally, Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and decreased their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th.

Perspective Therapeutics Stock Up 8.5 %

Shares of NYSE:CATX traded up $0.27 on Friday, hitting $3.43. 1,113,081 shares of the company's stock were exchanged, compared to its average volume of 1,043,828. Perspective Therapeutics has a 12 month low of $2.70 and a 12 month high of $19.05. The business's 50 day simple moving average is $4.29 and its two-hundred day simple moving average is $9.99.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In related news, Director Heidi Henson bought 25,975 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The shares were purchased at an average cost of $3.85 per share, with a total value of $100,003.75. Following the completion of the acquisition, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johan M. Spoor bought 14,500 shares of the business's stock in a transaction dated Monday, November 25th. The shares were purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the acquisition, the chief executive officer now owns 152,072 shares in the company, valued at approximately $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 67,570 shares of company stock valued at $256,789. Insiders own 3.52% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CATX. The Manufacturers Life Insurance Company lifted its holdings in Perspective Therapeutics by 8.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company's stock valued at $274,000 after purchasing an additional 1,672 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company's stock worth $783,000 after purchasing an additional 3,211 shares during the last quarter. US Bancorp DE grew its holdings in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after buying an additional 3,866 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics in the third quarter valued at about $57,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Perspective Therapeutics by 24.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock valued at $333,000 after buying an additional 4,844 shares during the period. Hedge funds and other institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.